Caffeine and Sodium Citrate Ingestion
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
A positive ergogenic effect of sodium citrate and caffeine ingestion in a short-term, high-intensity exercise task was shown by several studies. These studies were conducted with healthy, able-bodied subjects.
The aim of the study is to investigate whether caffeine or sodium citrate ingestion could enhance performance in spinal cord injured wheelchair athletes. It is a double blind, placebo controlled and randomized study.
| Condition | Intervention |
|---|---|
|
Dietary Supplements Heart Rate/Drug Effects Lactic Acid/Metabolism Physical Education and Training/Methods Wheelchairs |
Dietary Supplement: Caffeine Dietary Supplement: Sodium Citrate Dietary Supplement: Mannitol Dietary Supplement: Sodium Chloride |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Factorial Assignment Masking: Double Blind (Subject, Caregiver, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Effects of Caffeine and Sodium Citrate Ingestion in 1500m Wheelchair Racing Athletes |
- Time [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]Time to complete 1500m
- Heart Rate [ Time Frame: during study phase of 3 week (4 tests) ] [ Designated as safety issue: No ]Heart Rate measured from 2min before the test until 5min after the 1500m-test.
- Lactate Concentration [ Time Frame: during the 3 weeks study phase ] [ Designated as safety issue: No ]1min before starting the warm up, 15s after the end of the warm up, 15s after completing the test, 2min/4min/6min/8min/10min after the test
- blood pH, sodium concentration and plasma bicarbonate [ Time Frame: during the 3 weeks of study phase ] [ Designated as safety issue: No ]1min before starting with the ingestion of the fluid, immediately before starting the warm up, just immediately before starting the 1500m test.
- Oxygen Consumption [ Time Frame: during 3 weeks of study phase ] [ Designated as safety issue: No ]oxygen consumption (VO2(ml/min/kg), VCO2(ml/min), RER (VCO2/VO2)) starting of the measurement is 2min before the start of the 1500m and ends 2min after having completed the 1500m
- rating of gastrointestinal stress [ Time Frame: during the 3 weeks of study phase ] [ Designated as safety issue: No ]1min before starting to drink the fluid, 2min before starting with the warm up, 2min before the test and 2min after having completed the 1500m
- Rating of Perceived Exertion (RPE) [ Time Frame: during the 3 weeks of study phase ] [ Designated as safety issue: No ]15s after the end of the warm up, 15s after having completed the 1500m
| Enrollment: | 9 |
| Study Start Date: | February 2012 |
| Study Completion Date: | September 2012 |
| Primary Completion Date: | September 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Caffeine
6mg per kg bodyweight ingested 60min before test
|
Dietary Supplement: Caffeine
gelatine capsule 6mg/kg bodyweight 60min prior test
Dietary Supplement: Sodium Chloride
sodium chloride diluted in 7dl water 0.045g/kg bodyweight 120-90min prior test
|
|
Placebo Comparator: Placebo
Sodium chloride and mannitol as placebo are ingested by the athlete
|
Dietary Supplement: Mannitol
gelatine capsule filled with mannitol (100mg per capsule) ingested 60min prior test
Dietary Supplement: Sodium Chloride
sodium chloride diluted in 7dl water 0.045g/kg bodyweight 120-90min prior test
|
|
Active Comparator: Sodium Citrate
sodium citrate diluted in 7dl water, ingestion 120 to 90min prior test
|
Dietary Supplement: Sodium Citrate
0.5g/kg bodyweight diluted in 7dl water ingested 120-90min prior test
Dietary Supplement: Mannitol
gelatine capsule filled with mannitol (100mg per capsule) ingested 60min prior test
|
|
Active Comparator: Caffeine and Sodium Citrate
sodium citrate 120-90min prior test capsules:60min prior test
|
Dietary Supplement: Caffeine
gelatine capsule 6mg/kg bodyweight 60min prior test
Dietary Supplement: Sodium Citrate
0.5g/kg bodyweight diluted in 7dl water ingested 120-90min prior test
|
Detailed Description:
The athletes have to complete four 1500m tests on a training roller. Before each treatment they get different supplementations. Once they get sodium citrate and a placebo, once caffeine and a placebo, once sodium citrate and caffeine and for the fourth treatment they get twice a placebo. Two hours after starting with the supplementation they have to complete the 1500m as fast as possible. Time to complete 1500m, blood pH, plasma bicarbonate, sodium concentration, heart rate, oxygen consumption, blood lactate concentration and rate of perceived exertion (RPE) were measured.
Eligibility| Ages Eligible for Study: | 18 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- wheelchair athletes
- national team
- category T53 and T54
Exclusion Criteria:
- medicated
- pregnant (for women)
- cardiovascular and respiratory diseases
Contacts and Locations| Switzerland | |
| Swiss Paraplegic Centre | |
| Nottwil, Lucerne, Switzerland, 6207 | |
| Principal Investigator: | Claudio Perret, Dr. sc. nat. | Swiss Paraplegic Centre Nottwil |
More Information
No publications provided
| Responsible Party: | Swiss Paraplegic Centre Nottwil |
| ClinicalTrials.gov Identifier: | NCT01591226 History of Changes |
| Other Study ID Numbers: | JF_001 |
| Study First Received: | April 3, 2012 |
| Last Updated: | May 10, 2013 |
| Health Authority: | Switzerland: Ethikkommission |
Keywords provided by Swiss Paraplegic Centre Nottwil:
|
caffeine sodium citrate exercise performance wheelchair athletes 1500m |
Additional relevant MeSH terms:
|
Caffeine Citric Acid Mannitol Central Nervous System Stimulants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
Purinergic P1 Receptor Antagonists Purinergic Antagonists Purinergic Agents Neurotransmitter Agents Anticoagulants Hematologic Agents Chelating Agents Diuretics, Osmotic Diuretics Natriuretic Agents Cardiovascular Agents |
ClinicalTrials.gov processed this record on May 22, 2013